Reaction Details Report a problem with these data
Target
Interleukin-2
Ligand
BDBM50579802
Substrate
n/a
Meas. Tech.
ChEMBL_2145451 (CHEMBL5029731)
Kd
851±n/a nM
Citation
 Liu, F; Ul Amin, T; Liang, D; Park, MS; Alhamadsheh, MM Enhancing the Pharmacokinetic Profile of Interleukin 2 through Site-Specific Conjugation to a Selective Small-Molecule Transthyretin Ligand. J Med Chem 64:14876-14886 (2021) [PubMed]  Article 
Target
Name:
Interleukin-2
Synonyms:
IL-2 | IL2 | IL2_HUMAN | INN=Aldesleukin | Interleukin-2 | Interleukin-2 (IL-2) | T-cell growth factor | TCGF
Type:
Enzyme
Mol. Mass.:
17630.05
Organism:
Homo sapiens (Human)
Description:
P60568
Residue:
153
Sequence:
MYRMQLLSCIALSLALVTNSAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWITFCQSIISTLT
  
Inhibitor
Name:
BDBM50579802
Synonyms:
CHEMBL5081901
Type:
Small organic molecule
Emp. Form.:
C42H59N7O11
Mol. Mass.:
837.9582
SMILES:
Cc1n[nH]c(C)c1CCCOc1cc(OCCCc2cn(CCOCCOCCOCCOCCNC(=O)C3CCC(CN4C(=O)C=CC4=O)CC3)nn2)cc(c1)C(O)=O |c:47,(9.58,-37.95,;8.12,-38.43,;7.64,-39.9,;6.1,-39.89,;5.63,-38.43,;4.16,-37.96,;6.87,-37.52,;6.87,-35.98,;5.53,-35.21,;5.53,-33.67,;6.87,-32.9,;6.87,-31.36,;8.2,-30.59,;8.2,-29.04,;9.53,-28.27,;10.87,-29.03,;12.2,-28.26,;13.53,-29.02,;14.86,-28.25,;16.28,-28.86,;17.3,-27.71,;18.83,-27.87,;19.73,-26.62,;21.27,-26.77,;22.17,-25.52,;23.7,-25.68,;24.6,-24.43,;26.13,-24.59,;27.03,-23.34,;28.56,-23.49,;29.46,-22.24,;31,-22.4,;31.9,-21.15,;33.43,-21.3,;34.33,-20.05,;35.86,-20.21,;36.76,-18.96,;36.13,-17.56,;38.29,-19.12,;38.92,-20.52,;40.44,-20.68,;41.35,-19.43,;42.88,-19.59,;43.51,-21,;45.02,-21.32,;46.16,-20.28,;45.18,-22.85,;43.77,-23.47,;42.74,-22.33,;41.21,-22.49,;40.72,-18.03,;39.18,-17.86,;16.53,-26.38,;15.02,-26.71,;6.86,-28.28,;5.54,-29.05,;5.53,-30.59,;4.2,-28.28,;4.2,-26.74,;2.86,-29.05,)|
Structure:
Search PDB for entries with ligand similarity: